Sanofi India · NSE: SANOFI · BSE: 500674
Q3 FY25 results · Oct–Dec 2024
Sanofi India reported revenue from operations of ₹514.90 crore (down 25.8% from Q3 FY24) and net profit of ₹91.30 crore (down 33.7% from Q3 FY24) for Q3 FY25 (Oct–Dec 2024), on a consolidated basis.
| Item | Q3 FY25 | Q3 FY24 | YoY | Q2 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 514.90 | 693.90 | −25.8% | 524.00 | −1.7% |
| Other income | 5.90 | 12.00 | −50.8% | 2.30 | +156.5% |
| Total income | 520.80 | 705.90 | −26.2% | 526.30 | −1.0% |
| Profit before tax | 122.20 | 188.80 | −35.3% | 112.59 | +8.5% |
| Net profit for the period | 91.30 | 137.70 | −33.7% | 82.19 | +11.1% |
| EPS, basic (₹) | 39.64 | 59.79 | −33.7% | 35.69 | +11.1% |
| Net margin (%) | 17.7 | 19.8 | 15.7 |
| Item | Q3 FY25 | Q3 FY24 | YoY | Q2 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 514.90 | 693.90 | −25.8% | 524.00 | −1.7% |
| Other income | 5.90 | 12.00 | −50.8% | 2.30 | +156.5% |
| Total income | 520.80 | 705.90 | −26.2% | 526.30 | −1.0% |
| Profit before tax | 122.20 | 188.80 | −35.3% | 112.59 | +8.5% |
| Net profit for the period | 91.30 | 137.70 | −33.7% | 82.19 | +11.1% |
| EPS, basic (₹) | 39.64 | 59.79 | −33.7% | 35.69 | +11.1% |
| Net margin (%) | 17.7 | 19.8 | 15.7 |
Consolidated
- Filed with BSE
- 28 Feb 2025, 16:17 IST
- Board meeting
- 27 Feb 2025
- Period
- 01 Oct 2024 to 31 Dec 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 28 Feb 2025, 16:17 IST
- Board meeting
- 27 Feb 2025
- Period
- 01 Oct 2024 to 31 Dec 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE